Gene · 4070
Papers3,230
Newest first. Swiss-Prot's references are curated; PubTator's text mining finds papers that name the gene, not always ones about it.
601 to 620 of 3,230
Download this page as JSON| Title | Journal | Year | PMID | Found by | Source |
|---|---|---|---|---|---|
| Targeting the tumour cell surface in advanced prostate cancer. | Nat Rev Urol | 2025 | 40169837 | PubTator, text mining | PubMed |
| Advances in adoptive cell therapies in small cell lung cancer. | Explor Target Antitumor Ther | 2025 | 40160238 | PubTator, text mining | PubMed |
| New Radiopharmaceutical Tracers in Breast Cancer Diagnosis and Therapy. | Anticancer Agents Med Chem | 2025 | 40143388 | PubTator, text mining | PubMed |
| Identification of Tumor-Specific Surface Proteins Enables Quantification of Extracellular Vesicle Subtypes for Early Detection of Pancreatic Ductal Adenocarcinoma. | Adv Sci (Weinh) | 2025 | 40130819 | PubTator, text mining | PubMed |
| Advances in Antibody-Drug Conjugates for Endometrial Cancer. | Mol Cancer Ther | 2025 | 40111079 | PubTator, text mining | PubMed |
| Deciding where Trop-2 directed antibody drug conjugates work in non-small cell lung cancer: the not so straightforward road. | Transl Cancer Res | 2025 | 40104722 | PubTator, text mining | PubMed |
| The TROP2 paradox: enhancing precision in immunotherapy for advanced non-small cell lung cancer patients-a commentary. | Transl Cancer Res | 2025 | 40104697 | PubTator, text mining | PubMed |
| Proteomic Changes Associated With Endogenous FBXW7 Mutations in Moderately Differentiated Endometrial Cancer Cells Include Increased TROP2 and Galectin-3 Levels. | Cancer Med | 2025 | 40087851 | PubTator, text mining | PubMed |
| Spatial Expression of HER2, NECTIN4, and TROP-2 in Muscle-Invasive Bladder Cancer and Metastases: Implications for Pathological and Clinical Management. | Mod Pathol | 2025 | 40086591 | PubTator, text mining | PubMed |
| Preclinical evaluation of a novel antibody-drug conjugate OBI-992 for Cancer therapy. | Sci Rep | 2025 | 40082588 | PubTator, text mining | PubMed |
The PESGA Trial: A Prospective, Open-Label, Single-Arm, Phase II Study to Evaluate First Line Therapy for Extensive-Stage Small Cell Lung Cancer (ES-SCLC) Patients, Treated by Induction Carboplatin/Etoposide/Pembrolizumab Followed by Maintenance of Pembrolizumab/ Sacituzumab Govitecan. | Clin Lung Cancer | 2025 | 40064573 | PubTator, text mining | PubMed |
| Prognostic Value of Trop-2 Expression in Nonmetastatic Triple-Negative Breast Cancer and Correlation With Emerging Biomarkers. | Cancer Med | 2025 | 40059728 | PubTator, text mining | PubMed |
| ImmunoPET Imaging of Trop2 Expression in Bladder Cancer Using [64Cu]Cu-NOTA-Trodelvy. | Mol Pharm | 2025 | 40059341 | PubTator, text mining | PubMed |
| Noninvasive molecular imaging using anti-Trop-2 aptamer for targeted therapy of small cell lung cancer. | J Nanobiotechnology | 2025 | 40050871 | PubTator, text mining | PubMed |
| Quantitative Protein Expression of Antibody-Drug Conjugate Targets in EGFR Mutated and Wild-type Non-Small Cell Lung Cancer. | Clin Cancer Res | 2025 | 40047548 | PubTator, text mining | PubMed |
| Uncovering potential targets for antibody-drug conjugates in the treatment of gynecologic malignancies. | Front Pharmacol | 2025 | 40046734 | PubTator, text mining | PubMed |
| Targeting FAK improves the tumor uptake of antibody-drug conjugates to strengthen the anti-cancer responses. | iScience | 2025 | 40040813 | PubTator, text mining | PubMed |
| Reinventing chemotherapy. | Oncologist | 2025 | 40036587 | PubTator, text mining | PubMed |
| Exceptional response to TROP2 inhibition with sacituzumab govitecan in a patient with small cell carcinoma of the breast: a case report. | Ther Adv Med Oncol | 2025 | 40017901 | PubTator, text mining | PubMed |
| ImmunoPET imaging of Trop2 expression in triple-negative breast cancer using [64Cu]Cu-NOTA-Trodelvy-F(ab')2. | Eur J Nucl Med Mol Imaging | 2025 | 39994021 | PubTator, text mining | PubMed |
gene-search-2026-11-11-0.2.0
Sources 12
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- EMBL-EBI's patent proteinsNo added restrictions. Attribution expected
- GenBank's patent filesNo restrictions from NCBI. Submitters may hold rights
- HGNCCC0
- NCBI GenePublic domain (US government)
- NIH's project files and grant-paper linksPublic domain
- Open TargetsCC0 1.0
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- EMBL-EBI's patent proteinsEMBL-EBI's patent protein files from the EPO, JPO, KIPO and USPTO. EMBL-EBI: "EMBL-EBI itself places no additional restrictions on the use or redistribution of the data available via its Data Resources and Tools other than those provided by the original data owners" and "EMBL-EBI expects attribution (e.g. in publications, services or products) for the use of any of its Data Resources and Tools." Read on 11 Nov 2026 at https://www.ebi.ac.uk/about/terms-of-use
- GenBank's patent filesGenBank's patent files. NCBI: "NCBI places no restrictions on the use or distribution of the GenBank data. However, some submitters may claim patent, copyright, or other intellectual property rights in all or a portion of the data they have submitted." Read on 11 Nov 2026 at https://www.ncbi.nlm.nih.gov/genbank/about/
- HGNCCC0: https://www.genenames.org/about/license/
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH's project files and grant-paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/genes/v1/4070/papers?page=31